Detalhe da pesquisa
1.
A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS).
Lung Cancer
; 99: 94-101, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27565921